In February of 2014, CTTI’s founding Executive Director Judy Kramer retired and today we’d like to pay tribute to her legacy. She most recently served as CTTI’s Senior Scientific Advisor and as Professor Emerita of Medicine at Duke. In addition to establishing this CTTI, Judy provided scientific guidance on individual CTTI projects and she played a significant role in communicating the results of these projects through publications and presentations at national and international meetings. She also advanced our mission by participating in the efforts of other non-profit organizations with similar goals.

Judy is known for her genuine passion and unfaltering conviction to improve and transform clinical trials, as well as her ongoing commitment to patient-centeredness and clinical trial safety issues. These attributes permeated through all of our interactions with her and aside from her valuable professional contributions to CTTI and Duke, Judy had a lasting positive personal influence on her colleagues.

Luckily for the clinical trial enterprise, Judy will continue to stay involved with FDA advisory committees. She will also likely have additional interactions with CTTI through her Professor Emerita role at Duke. Please join me in wishing Judy all the best in this next phase of her life, which will include a larger proportion of time devoted to travel, taking beautiful pictures, and her family. She and her husband, Lloyd, are looking forward to spending more time with their four granddaughters.

– Pamela Tenaerts, MD, MBA
Executive Director, CTTI

As a tribute to Judy’s years of service, we’d like to share a recent video featuring our retired founding Executive Director’s explanation of the importance of randomization in clinical trials: